What is Leerink Partnrs' Forecast for Exelixis Q1 Earnings?

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share estimates for shares of Exelixis in a research note issued on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of $0.37 per share for the quarter, up from their previous estimate of $0.36. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis' Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.71 EPS, FY2025 earnings at $2.23 EPS and FY2026 earnings at $2.75 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Several other research firms have also weighed in on EXEL. Citigroup upped their price target on Exelixis from $38.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. UBS Group reissued an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Oppenheimer downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Stifel Nicolaus increased their target price on shares of Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research report on Wednesday, February 12th. Finally, StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Exelixis currently has an average rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Trading Up 1.8 %

NASDAQ:EXEL traded up $0.71 during trading hours on Wednesday, hitting $39.60. 1,991,518 shares of the stock traded hands, compared to its average volume of 2,157,631. The firm has a market cap of $10.91 billion, a price-to-earnings ratio of 22.37, a PEG ratio of 1.13 and a beta of 0.57. The firm has a 50 day moving average price of $36.95 and a 200 day moving average price of $35.04. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Institutional Trading of Exelixis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB grew its position in Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock worth $63,000 after buying an additional 290 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Exelixis by 6.1% in the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 307 shares during the period. Balyasny Asset Management L.P. grew its holdings in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock worth $573,000 after purchasing an additional 317 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Exelixis by 4.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock valued at $235,000 after purchasing an additional 330 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its stake in shares of Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock valued at $1,937,000 after purchasing an additional 354 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Exelixis news, Director Mary C. Beckerle sold 12,210 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now owns 30,406 shares of the company's stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the transaction, the chief financial officer now directly owns 779,607 shares in the company, valued at approximately $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 in the last quarter. 2.85% of the stock is currently owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.